{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:38Z","timestamp":1790208038689,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004965","name":"Sixth Framework Programme","doi-asserted-by":"publisher","award":["EU FP6 (EUROSCA)"],"award-info":[{"award-number":["EU FP6 (EUROSCA)"]}],"id":[{"id":"10.13039\/501100004965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004965","name":"Sixth Framework Programme","doi-asserted-by":"publisher","award":["503304"],"award-info":[{"award-number":["503304"]}],"id":[{"id":"10.13039\/501100004965","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Ministry of Education and Research","award":["GeneMove"],"award-info":[{"award-number":["GeneMove"]}]},{"name":"Polish Ministry of Scientific Research and Information Technology"},{"name":"Hungarian Funding Agency","award":["NKFIH 119540"],"award-info":[{"award-number":["NKFIH 119540"]}]},{"DOI":"10.13039\/100011199","name":"FP7 Ideas: European Research Council","doi-asserted-by":"publisher","award":["n\u00b0 2012-305121 \u201cIntegrated European-omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)\u201d"],"award-info":[{"award-number":["n\u00b0 2012-305121 \u201cIntegrated European-omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)\u201d"]}],"id":[{"id":"10.13039\/100011199","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00415-018-8954-0","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T08:35:41Z","timestamp":1530261341000},"page":"2040-2051","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias"],"prefix":"10.1007","volume":"265","author":[{"given":"Heike","family":"Jacobi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie Tezenas","family":"du Montcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Giunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arron","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Labrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Durr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Marelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Nanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rakowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sulek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sobanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Schmitz-H\u00fcbsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Sch\u00f6ls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Hengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Baliko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Melegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Filla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Antenora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Berciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart P.","family":"van de Warrenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Timmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Boesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Nachbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Suk","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pandolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg B.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey Tanguy","family":"Melac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhassane","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klockgether","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"issue":"10","key":"8954_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrn.2017.92","volume":"18","author":"HL Paulson","year":"2017","unstructured":"Paulson HL, Shakkottai VG, Clark HB, Orr HT (2017Oct) Polyglutamine spinocerebellar ataxias\u2014from genes to potential treatments. Nat Rev Neurosci 18(10):613\u2013626","journal-title":"Nat Rev Neurosci"},{"key":"8954_CR2","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH) (2009) Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf . Accessed Dec 2009"},{"issue":"2","key":"8954_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s12325-016-0463-x","volume":"34","author":"PF Recinos","year":"2017","unstructured":"Recinos PF, Dunphy CJ, Thompson N, Schuschu J, Urchek JL 3rd, Katzan IL (2017) Patient satisfaction with collection of patient-reported outcome measures in routine care. Adv Ther 34(2):452\u2013465","journal-title":"Adv Ther"},{"issue":"2","key":"8954_CR4","first-page":"38","volume":"10","author":"S Bryan","year":"2014","unstructured":"Bryan S, Davis J, Broesch J, Doyle-Waters MM, Lewis S, McGrail K et al (2014) Choosing your partner for the PROM: a review of evidence on patient-reported outcome measures for use in primary and community care. Healthc Policy 10(2):38\u201351","journal-title":"Healthc Policy"},{"issue":"5","key":"8954_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mds.22740","volume":"25","author":"T Schmitz-H\u00fcbsch","year":"2010","unstructured":"Schmitz-H\u00fcbsch T, Coudert M, Giunti P, Globas C, Baliko L, Fancellu R et al (2010) Self-rated health status in spinocerebellar ataxia\u2014results from a European multicenter study. Mov Disord 25(5):587\u2013595","journal-title":"Mov Disord"},{"issue":"5","key":"8954_CR6","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/mds.23698","volume":"26","author":"T Schmitz-H\u00fcbsch","year":"2011","unstructured":"Schmitz-H\u00fcbsch T, Coudert M, Tezenas du Montcel S, Giunti P, Labrum R, D\u00fcrr A et al (2011) Depression comorbidity in spinocerebellar ataxia. Mov Disord 26(5):870\u2013876","journal-title":"Mov Disord"},{"key":"8954_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.parkreldis.2015.11.021","volume":"22","author":"RY Lo","year":"2016","unstructured":"Lo RY, Figueroa KP, Pulst SM, Perlman S, Wilmot G, Gomez C et al (2016) Depression and clinical progression in spinocerebellar ataxias. Parkinsonism Relat Disord 22:87\u201392","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"8954_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000096276","volume":"10","author":"CR Cecchin","year":"2007","unstructured":"Cecchin CR, Pires AP, Rieder CR, Monte TL, Silveira I, Carvalho T et al (2007) Depressive symptoms in Machado\u2013Joseph disease (SCA3) patients and their relatives. Community Genet 10(1):19\u201326","journal-title":"Community Genet"},{"issue":"13","key":"8954_CR9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1212\/01.wnl.0000325057.33666.72","volume":"71","author":"T Schmitz-H\u00fcbsch","year":"2008","unstructured":"Schmitz-H\u00fcbsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L et al (2008) Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology 71(13):982\u2013989","journal-title":"Neurology"},{"issue":"11","key":"8954_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1212\/WNL.0b013e31822e7ca0","volume":"77","author":"H Jacobi","year":"2011","unstructured":"Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P et al (2011) The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology 77(11):1035\u20131041","journal-title":"Neurology"},{"issue":"11","key":"8954_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","volume":"14","author":"H Jacobi","year":"2015","unstructured":"Jacobi H, du Montcel ST, Bauer P, Giunti P, Cook A, Labrum R et al (2015) Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol 14(11):1101\u20131108","journal-title":"Lancet Neurol"},{"key":"8954_CR12","doi-asserted-by":"crossref","unstructured":"(1996) Unified Huntington\u2019s Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 11(2):136\u2013142","DOI":"10.1002\/mds.870110204"},{"issue":"3","key":"8954_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group (1990 Dec) EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16(3):199\u2013208","journal-title":"Health Policy"},{"key":"8954_CR14","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","volume":"282","author":"RL Spitzer","year":"1999","unstructured":"Spitzer RL, Kroenke K, Williams JB (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA 282:1737\u20131744","journal-title":"JAMA"},{"key":"8954_CR15","doi-asserted-by":"crossref","unstructured":"Schmitz-H\u00fcbsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66(11):1717\u20131720","DOI":"10.1212\/01.wnl.0000219042.60538.92"},{"issue":"3","key":"8954_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s12311-012-0421-3","volume":"12","author":"H Jacobi","year":"2013","unstructured":"Jacobi H, Rakowicz M, Rola R, Fancellu R, Mariotti C, Charles P et al (2013) Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument. Cerebellum 12(3):418\u2013428","journal-title":"Cerebellum"},{"issue":"4","key":"8954_CR17","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/j.1541-0420.2006.00573.x","volume":"62","author":"C Proust","year":"2006","unstructured":"Proust C, Jacqmin-Gadda H, Taylor JM, Ganiayre J, Commenges D (2006) A nonlinear model with latent process for cognitive evolution using multivariate longitudinal data. Biometrics 62(4):1014\u20131024","journal-title":"Biometrics"},{"key":"8954_CR18","first-page":"275","volume-title":"Pattern-mixture models. Linear mixed models for longitudinal data","author":"G Verbeke","year":"2000","unstructured":"Verbeke G, Molenberghs G (2000) Pattern-mixture models. Linear mixed models for longitudinal data. Springer, New York, pp\u00a0275\u2013293"},{"issue":"3 suppl","key":"8954_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/00005650-198903001-00015","volume":"27","author":"LE Kazis","year":"1989","unstructured":"Kazis LE, Anderson JJ, Meenan RF (1989) Effect sizes for interpreting changes in health status. Med Care 27(3 suppl):178\u2013189","journal-title":"Med Care"},{"issue":"Suppl 2","key":"8954_CR20","first-page":"S65","volume":"64","author":"T Simuni","year":"2008","unstructured":"Simuni T, Sethi K (2008) Nonmotor manifestations of Parkinson\u2019s disease. Ann Neurol 64(Suppl 2):S65\u2013S80","journal-title":"Ann Neurol"},{"issue":"9","key":"8954_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16(9):606\u2013613","journal-title":"J Gen Intern Med"},{"key":"8954_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpsychores.2009.05.003","volume":"68","author":"TA Furukawa","year":"2010","unstructured":"Furukawa TA (2010) Assessment of mood: guides for clinicians. J Psychosom Res 68:581\u2013589","journal-title":"J Psychosom Res"},{"key":"8954_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1471-244X-12-73","volume":"3","author":"T Inoue","year":"2012","unstructured":"Inoue T, Tanaka T, Nakagawa S, Nakato Y, Kameyama R, Boku S et al (2012) Utility and limitations of PHQ-9 in a clinic specializing in psychiatric care. BMC Psychiatry 3:12:73 Jul","journal-title":"BMC Psychiatry"},{"issue":"11","key":"8954_CR24","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1007\/s11606-007-0333-y","volume":"22","author":"S Gilbody","year":"2007","unstructured":"Gilbody S, Richards D, Brealey S, Hewitt C (2007Nov) Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med 22(11):1596\u20131602","journal-title":"J Gen Intern Med"},{"issue":"1","key":"8954_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1176\/appi.neuropsych.11030057","volume":"24","author":"JC Thompson","year":"2012","unstructured":"Thompson JC, Harris J, Sollom AC, Stopford CL, Howard E, Snowden JS et al (2012) Longitudinal evaluation of neuropsychiatric symptoms in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci 24(1):53\u201360","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"8954_CR26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000343210","volume":"13","author":"E Duijn van","year":"2014","unstructured":"van Duijn E, Reedeker N, Giltay EJ, Eindhoven D, Roos RA, van der Mast RC (2014) Course of irritability, depression and apathy in Huntington\u2019s disease in relation to motor symptoms during a two-year follow-up period. Neurodegener Dis 13(1):9\u201316","journal-title":"Neurodegener Dis"},{"issue":"4","key":"8954_CR27","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mds.22412","volume":"24","author":"AK Ho","year":"2009","unstructured":"Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA (2009) Health-related quality of life in Huntington\u2019s disease: which factors matter most? Mov Disord 24(4):574\u2013578","journal-title":"Mov Disord"},{"issue":"3","key":"8954_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/mds.870070302","volume":"7","author":"RN Rosenberg","year":"1992","unstructured":"Rosenberg RN (1992) Machado\u2013Joseph disease: an autosomal dominant motor system degeneration. Mov Disord 7(3):193\u2013203","journal-title":"Mov Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-8954-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8954-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8954-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T15:06:53Z","timestamp":1661526413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-8954-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["8954"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-8954-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,29]]},"assertion":[{"value":"30 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"H. Jacobi reports no disclosures. S. Tezenas du Montcel reports no disclosures. P. Bauer is executive board member at Centogene AG, Rostock, GER. He holds stock options in the company. He received speaker honoraria from Actelion Pharmaceuticals, Aschwil, CH. His research work was partly funded by EC Grants (2012-305121). P. Giunti received research support from Pfizer, Reata, Acetalion unrelated to the topic of this paper. She received funding for a trip to attend a meeting organised by Acetalion. A. Cook reports no disclosures. R. Labrum reports no disclosures. M. Parkinson reports no disclosures. A. Durr holds a patent \u201cAnaplerotic therapy of Huntington disease and other polyglutamine diseases\u201d, BIO06353 Mochel\/Durr (EP 06291873.5, 12\/4\/2006). A. Brice serves on the scientific advisory board for FWO (Research Foundation Flanders), ERC (European Research Council), as an editorial board member for the journals Neurology and Clinical Neuroscience, Brain, Neurodegenerative Diseases, The Cerebellum, Neurogenetics. He received Grants from the public French Research Agency (ANR), EU, France Parkinson Association, RDS (Roger de Spoelberch Foundation), FDF (Fondation de France) and FRM (Fondation pour la recherche m\u00e9dicale). P. Charles reports no disclosures. C. Marelli receveid financial support for travel expenses and congres participation from Acetlion Pharmaceutical (unrelated to this study). C. Mariotti received funding for an educational seminar from Roche Pharmaceuticals and research support from the Italian Ministry of Health (Grant # RF-2011-02347420), CHDI Foundation and Telethon UILDM (Grant # GUP15009). L. Nanetti, received research support from the Italian Ministry of Health (Grant # GR-2013-02357821). L. Sarro received research support from the Italian Ministry of Health (Grant # RF-2011-02347420). M. Rakowicz received research support from the Polish Ministry of Science and Higher Education Grant 674N-RISCA\/2010-2014 and Clinical TeleNeuroforma; Grant IS-2\/230\/NCBR\/2015 2016 from the National Science Center Poland and a Speaker\u2019s honorarium from the TERMEDIA Ltd. A. Sulek reports no disclosures. (A) Sobanska part in Clinical TeleNeuroforma project sponsored by Grant IS-2\/230\/NCBR\/2015. T. Schmitz-H\u00fcbsch reports no conflicts of interest. She was funded by EU and Bundesminsterium f\u00fcr Wirtschaft und Energie. L. Sch\u00f6ls reports no disclosures relevant to this manuscript. L. Sch\u00f6ls received Grants from EU FP7 and the Deutsche Forschungsgemeinschaft (DFG) during conduct of this study outside the submitted work. H. Hengel reports no disclosures. L. Baliko reports no disclosures. (B) Melegh reports no disclosures. A. Filla reports no disclosures. (A) Antenora reports no disclosures. J. Infante received research support from CIBERNED and honoraria as speaker and financing the attendance at meetings from Zambon and Abbvie. J. Berciano reports no disclosures. (B) van de Warrenburg is receiving or has received research Grants from Hersenstichting, Gossweiler Foundation, Radboud university medical centre, BBMRI-NL, ZonMW, and Bioblast Pharma. D. Timmann was funded by the German Research Foundation (DFG), Mercator Research Center Ruhr (MERCUR) and the German Heredoataxia Foundation (DHAG). S. Szymanski reports no disclosures. S. Boesch served on the advisory boards for Gruenenthal and Abbvie, received honoraria from Ipsen, Allergan, Abbvie, Novartis, Gruenenthal and Reata and the following Grants: European Friedreich Ataxia Consortium for Translational Studies (EFACTS), FP7 Health (HEALTH-F2-2010-242193), E-Rare-3 \u201cClinical research for new therapeutic uses of already existing molecules (repurposing) in rare diseases\u201d (E-Rare-3JTC2016). W. Nachbauer reports no disclosures. J.-S. Kang served as consultant and received honoraria and funding for congress fees and travel expenses from Merz Pharma GmbH, received honoraria from Medtronic GmbH and funding for congress fees from Ipsen Pharma. M. Pandolfo served on the scientific advisory board for Voyager Therapeutics and Biomarin and as associate editor for Neurology Genetics, receives royalties from Athena Diagnostics and a research Grant to perform studies in cellular and animal models of Friedreich ataxia from Biomarin. J. Schulz reports Grants from BMBF (GeNeMove) Grants from EU (EUROSCA) during the conduct of the study; independent of the work presented here he receives Grants from the EU (HEALTH-F2-2010-242193). J. Schulz serves on scientific advisory boards for Lundbeck Inc., TEVA, Novartis, ForwardPharma and Lilly; he has received funding for travel and speaker honoraria from GlaxoSmithKline, Merz Pharmaceuticals, Medical Tribune, Lundbeck Inc., Pfizer Inc, Boehringer, Bayer. He serves as Editor-in-Chief of the Journal of Neurochemistry and Associate Editor for eNeuro. A.Tanguy worked for Lundbeck SAS and AbbVie Inc outside of the submitted work. A. Diallo reports no disclosures. T. Klockgether reports Grants from EU FP7 Neuromics, during the conduct of the study; personal fees from Biohaven, personal fees from ICON Clinical Research, personal fees from Atheneum, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the ethics committees of the participating centres and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}